Male Gynecomastia

Haynes, Bridgett A.; Mookadam, Farouk
August 2009
Mayo Clinic Proceedings;Aug2009, Vol. 84 Issue 8, p672
Academic Journal
Case Study
The article presents a case study of a 62-year-old man with known coronary artery disease and ischemic left ventricular dysfunction, and with severe gynecomastia. The patient had been under medication of spironolactone daily for eight years as part of his regimen for congestive heart failure. It discusses the pathological aspects of gynecomastia which is a well-described adverse effect of spironolactone and is related to dose and duration of treatment.


Related Articles

  • Facilitated PCI associated with worse outcomes than primary PCI.  // Reactions Weekly;3/4/2006, Issue 1091, p3 

    Discusses the findings of a research regarding tenecteplase-facilitated percutaneous coronary intervention (PCI). Association with worse outcomes than primary PCI; Analysis of whether facilitated PCI is more effective than primary PCI; Primary endpoint of mortality, shock or congestive heart...

  • Spironolactone.  // Reactions Weekly;9/19/2009, Issue 1270, p34 

    The article describes the case of a 62-year-old man with a history of coronary artery disease, ischaemic left ventricular dysfunction and congestive heart failure with depressed left ventricular ejection fraction. The man, who presented with chest discomfort, had been receiving sironolactone for...

  • Spironolactone.  // Reactions Weekly;3/10/2007, Issue 1142, p21 

    The article presents a case report of a man with congestive heart failure and was receiving spironolactone daily. It states that a condition called gynecomastia which is an increasing breast size in the patient during his treatment made his medication replaced by eplerenone. The author mentions...

  • Spironolactone.  // Reactions Weekly;7/14/2007, Issue 1160, p28 

    The article describes the case of a 76-year-old man who had Parkinson's disease with stable motor function and congestive heart failure (CHF). As a result of worsening CHF, he was given spironolactone. A week after treatment, he experienced abrupt motor deterioration. The drug was discontinued...

  • Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. Svensson, Morten; Gustafsson, Finn; Galatius, Soren; Hildebrandt, Per R; Atar, Dan // BMJ: British Medical Journal (International Edition);11/15/2003, Vol. 327 Issue 7424, p1141 

    Follows up congestive heart patients who were treated with spironolactone to determine if there were any predictors of harmful effects. How they chose the patients; Baseline characteristics of those studied; Finding that there were more frequent side effects than thought; Factors which predict...

  • Research on discharge for coronary patients.  // Healthcare Benchmarks & Quality Improvement;May2010, Vol. 17 Issue 5, p56 

    This article discusses the need for discharge planning in the care of patients with coronary and congestive heart failure. It references several studies which involve patients that are susceptible to adverse events and drug-drug interactions. It stresses the need of physicians and discharge...

  • Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine Clinical Use: A 12-Week, Open-Label, Post-Marketing Surveillance Study. Michel, Martin C.; Wetterauer, Ulrich; Vogel, Monika; De la Rosette, Jean J. M. C. H. // Drug Safety;2008, Vol. 31 Issue 6, p505 

    This article discusses a study of the muscarinic receptor antagonist solifenacin, which is used to treat patients with overactive bladders (OAB). Adverse drug reactions in patients with coronary heart disease (CHD) or congestive heart failure (CHF) are noted because of reports that solifenacin...

  • Older heart drug cuts death rate by 30%. Hensley, Scott // Modern Healthcare;07/26/99, Vol. 29 Issue 30, p24 

    Discusses the re-discovery of spironolactone, a drug that blocks the action of a hormone called aldosterone. Implications of the discovery of the drug on hospitals and health systems; Number of people hospitalized with congestive heart failure.

  • Old drug, new treatment for severe CHF.  // Brown University Long-Term Care Quality Advisor;Oct99, Vol. 11 Issue 10, p1 

    Reports that generic drug spironolactone has proved to be effective in treating life-threatening congestive heart failure, reducing the death rate by 30 percent. INSET: Aging heads need social support too.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics